30 results about "Prilocaine" patented technology

An anesthetic composition for use e.g. in the administration of a local anesthetic by injection comprises a first component, which comprises hyaluronidase, and a second component which comprises an anesthetic preparation. The composition is both effective and highly shelf stable, and has as an advantage that it may be stored and administered at room temperature. In a particular embodiment, the hyaluronidase is prepared in dry powder form, as by lyophilization. The anesthetic component may be selected from a group of known anesthetics, such as lidocaine, polocaine, xylocaine, novocaine, procaine, prilocaine, bupivacaine, mepivacaine, carbocaine, etidocaine and chincocaine. The composition may be prepared in unit dosage forms, including a single dosage form, for a variety of purposes, and such unit dosage forms may be prepared in a plural chambered syringe or like dispenser, whereby the components are not mixed until administration.

The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and / or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and / or lidocaine. The silicone-based gel may include additional active ingredients, such as NSAIDs, anticonvulsants, antidepressants, muscle relaxants, and / or other active ingredients.

The invention discloses a pharmaceutical composition, a patch, and preparation methods and application of the pharmaceutical composition and the patch. The pharmaceutical composition comprises a simplex anesthetic active ingredient, wherein the anesthetic active ingredient is composed of anesthetic active components dissolved in water and anesthetic active components in undissolved state; mass percentage of the anesthetic active ingredient in the pharmaceutical composition is higher than 2%; mass percentage of the anesthetic active components dissolved in water in the pharmaceutical composition is lower than 1%; and the anesthetic active ingredient is selected from lidocaine, tetracaine, bupivacaine, atecaine, cincocaine, dibucaine, eticaine, levobupivacaine, mepivacaine, propivacaine, ropivacaine, trimethylcaine, benzocaine or procaine. The pharmaceutical composition and the patch are capable of achieving continuous analgesic effects for 12-30 hours; moreover, the patch is capable ofresisting certain external pressing force so as to protect the covered formula layers from being squeezed out, thereby maintaining thickness of the formula layers.

The present invention provides a medical device, which comprises: a microneedle array, and a coating disposed on the microneedles, wherein the coating comprises: a local anesthetic selected from lidocaine, Prilocaine and combinations thereof; and local anesthetic dose sustained-release components selected from tetracaine, ropivacaine, bupivacaine, procaine and combinations thereof; wherein based on the solids in the coating The total weight of the local anesthetic is present in an amount of at least 1% by weight, and wherein the weight ratio of the local anesthetic and the dose-extending component is a non-eutectic weight ratio; a medical device comprising An array of dissolving microneedles comprising: a dissolvable matrix material; at least 1% by weight of a local anesthetic selected from the group consisting of lidocaine, prilocaine, and combinations thereof; and a local anesthetic dose sustained release component , which is selected from tetracaine, ropivacaine, bupivacaine, procaine, and combinations thereof; wherein the weight ratio of the local anesthetic and the dose-sustaining component is a non-eutectic weight ratio, and wherein the weight % based on the total weight of solids in all portions of the dissolvable microneedles containing the local anesthetic; a method of using the device to provide sustained release of a locally delivered dose of local anesthetic in mammalian tissue; and a method of manufacturing method of the device.

The present invention provides a medical device, which comprises: a microneedle array, and a coating disposed on the microneedles, wherein the coating comprises: a local anesthetic selected from lidocaine, Prilocaine and combinations thereof; and a local anesthetic dose sustained release component selected from the group consisting of alpha 1 adrenergic agonists, alpha 2 adrenergic agonists and combinations thereof; wherein based on the coating The total weight of solids, the local anesthetic is present in an amount of at least 1% by weight, and wherein the dose-extending component / local anesthetic weight ratio is at least 0.0001; a medical device comprising An array of dissolving microneedles comprising: a dissolvable matrix material; at least 1% by weight of a local anesthetic selected from the group consisting of lidocaine, prilocaine, and combinations thereof; and a local anesthetic dose sustained release component , the local anesthetic dose-sustaining release component is selected from α1 adrenergic agonist, α2 adrenergic agonist and combinations thereof; wherein the weight ratio of the dose-sustaining component / local anesthetic is at least 0.0001, and wherein the weight % based on the total weight of solids in all portions of the dissolvable microneedles containing the local anesthetic; a method of using the device to provide sustained release of a locally delivered dose of local anesthetic in mammalian tissue; and a method of manufacturing method of the device.

The invention provides a compound lidocaine cream pharmaceutical composition and a preparation method thereof. The pharmaceutical composition is prepared from effective doses of lidocaine and prilocaine as main drug raw materials, and polyoxyethylene hydrogenated castor oil, carbomer, sodium hydroxide and purified water as pharmaceutical auxiliary materials. The cream body of the present invention has good moisturization and applicability, low impurity content, good quality and little skin irritation.

The invention discloses a compound lidocaine aerosol and a preparation method thereof. 2 to 35 parts of propellant, 1 to 17.6 parts of polyvinyl alcohol and 0.1 to 1.75 parts of rutin derivatives; the present invention releases base forms of lidocaine and Prilocaine reaches the subcutaneous layer, and because polyvinyl alcohol is used to form a thin film on the skin surface, the dosage of lidocaine and prilocaine is reduced, and the safety of clinical use is enhanced; and because the treatment of male premature ejaculation is mainly to inhibit the penis The arterioles and capillary anterior sphincter dilate to relax the smooth muscle, thereby increasing the blood flow; the present invention adds rutin derivatives, improves capillary function, increases its elasticity and permeability, and avoids the traditional lidocaine Adverse reactions such as vascular bleeding caused by long-term use of drugs.

The invention provides a compound lidocaine medicine composition. The composition is prepared from lidocaine, prilocaine, an oil phase, a surfactant, a cosurfactant and water. According to the method, a hydrophilic drug prilocaine and a lipophilic drug lidocaine are introduced into a microemulsion system in a reasonable proportion. The system can be used for enhancing the transdermal permeation effect of the two drugs at the same time and greatly shortening the effect of local anaesthesia, can be applied to local cortex before injection to reduce patient pain and improve compliance, and can be applied to patients requiring operation as soon as possible to greatly reduce the waiting time of anaesthesia and shorten the operation time. Furthermore, the pharmaceutical composition has high stability, can be stored for 9 months at 25 DEG C and 40 DEG C, does not contain penetration enhancer, preservative, ionic polymer or other additives, and is simple in composition, high in quality, small in side effect and high in safety.